N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B

• Published in: Irish Veterinary Journal 2023-02, Vol.76 (1), p.3-3, Article 3
• Main Authors: Jang, In Sung, Yoon, Won Kyoung, Choi, Eun Wha
• Format: Article
• Language: English
• Subjects: Biomarker; Biomarkers; Blood pressure; Canine; Cardiac arrhythmia; Cardiovascular disease; Electrocardiography; Heart failure; Kidney diseases; Laboratories; Myxomatous mitral valve disease (MMVD); N-terminal pro-B-type natriuretic peptide (NT-proBNP); Peptides; Pulmonary arteries; Pulmonary hypertension; Radiography; Systemic hypertension
• ISSN: 2046-0481; 0368-0762; 2046-0481
• DOI: 10.1186/s13620-023-00233-0

Systemic hypertension affects the heart, and to the best of our knowledge, no study has investigated the effects of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in dogs with myxomatous mitral valve disease (MMVD) stage B and systemic hypertension. This study aimed to investigate the blood level of NT-proBNP and assess the selected echocardiographic variables in dogs with MMVD stage B according to the presence of systemic hypertension or normal blood pressure and in dogs without MMVD. The study group comprised 37 dogs with stage B MMVD (normotensive group, n = 30; systemic hypertension group, n = 7) and 13 dogs without MMVD. We evaluated NT-proBNP, blood pressure, complete blood count (CBC), and serum chemistry in all 50 dogs. We performed electrocardiography, radiography, and echocardiography on 44 dogs (37 dogs with MMVD and 7 dogs without MMVD). The NT-proBNP concentrations showed significant intergroup differences (p